

SITC IL-6 Supplemental Table 1

Target	Modulating agent	Regulatory Status	Brand Name	Manufacturer	MOA/Comments
IL-6 Modulation					
IL-6	tocilizumab	FDA-approved	Actemra	Genentech	Humanized anti-IL-6R mAb (receptor antagonist)
IL-6	siltuximab (CNTO 328)	FDA-approved	Sylvant	EUSA Pharma	Chimeric anti IL-6 mAb
IL-6	sarilumab	FDA-approved	Kevzara	Regeneron	Human anti-IL-6R mAb (receptor antagonist)
IL-6	satralizumab	in clinical trials		Roche	Humanized anti-IL-6R mAb (receptor antagonist)
IL-6	vobarilizumab (ALX-0061)	in clinical trials		Ablynx	Dual heavy-chain anti-IL-6R/anti-albumin nanobody (receptor antagonist)
IL-6	MEDI5117	in clinical trials (halted), preclinical		AstraZeneca (from MedImmune)	Affinity-optimized human anti-IL-6 mAb
IL-6	olokizumab (CDP6038)	in clinical trials		R-Pharm (Moscow) licensed from UCB	Humanized anti-IL-6 mAb
IL-6	elsilimomab (B-E8)	in clinical trials		Diaclone (France)	Murine anti-IL-6 mAb
IL-6	clazakizumab (BMS-945429)	in clinical trials		Vitaeris	Humanized anti-IL-6 mAb
IL-6	FE301	preclinical		Conaris Research Institute/Ferring	Soluble gp130-Fc fusion protein
IL-6	FM101	clinical trials		Femta Pharmaceuticals agreement with Lonza	Humanized anti-IL-6 mAb
IL-6	C326	clinical trials		Avidia	anti-Fc avimer protein
IL-6	Sant7	clinical trials			IL-6R Receptor superantagonist
IL-6	olamkicept (TJ301)	in clinical trials		I-MAB biopharma (from Ferring)	gp130-Fc fusion protein. Inhibits trans signaling
SOCS3	naringenin				natural product, pleiotropic activity claimed
SOCS3	flavone				natural product, pleiotropic activity claimed
JAK/STAT Modulation					

SITC IL-6 Supplemental Table 1

JAK/STAT	ruxolitinib	FDA-approved	Jakavi/Jakafi	Incyte/Novartis	JAK1/2 TKI
JAK/STAT	tofacitinib	FDA-approved	Xeljanz/Jakvins	Pfizer	JAK1/3 TKI
JAK/STAT	baricitinib	FDA-approved	Olumiant	Eli-Lilly/Incyte	JAK1/2 TKI
JAK/STAT	peficitinib	Japan-approved	Smyraf	Astellas	Pan-JAK TKI
JAK/STAT	decernotinib (VX-509)	in clinical trials		Vertex	JAK3 TKI
JAK/STAT	filgotinib (GLPG0634)	in clinical trials		Galapagos NV (Belgium) and Gilead	JAK1 TKI
JAK/STAT	solcitinib (GSK2586184 or GLPG0778)	in clinical trials/halted		Galapagos NV (Belgium) and GSK	JAK1 TKI
JAK/STAT	itacitinib (INCB039110)	in clinical trials		Incyte (Innovent Biologics in China)	JAK1 TKI
JAK/STAT	upadacitinib	FDA-approved	Rinvoq	AbbVie	JAK1 TKI
JAK/STAT	abrocitinib (PF-04965842)	in clinical trials		Pfizer	JAK1 TKI
JAK/STAT	ocacitinib	VETERINARY MEDICATION	Apoquel	Zoetis	JAK1 TKI
JAK/STAT	PF-06651600	in clinical trials		Pfizer	JAK3 TKI
JAK/STAT	BMS-986165	in clinical trials		BMS	Tyk2 TKI
JAK/STAT	pacritinib	in clinical trials		CTI biopharma (multiple partnerships and transfers, including Baxter and Shire)	JAK2 & IRAK1 TKI
JAK/STAT	cerdulatinib	in clinical trials		Portola Pharmaceuticals	JAK1/3 & Syk TKI
JAK/STAT	fedratinib	FDA-approved	Inrebic	Impact Biomedicines (Celgene)	JAK1/JAK2 TKI
JAK/STAT	gandotinib (LY-2784544)	in clinical trials		Eli-Lilly	multikinase TKI similar to staurosporin
JAK/STAT	lestaurtinib (CEP-701)	in clinical trials		Cephalon Pharmaceuticals	JAK2, FLT3 & TrkA TKI
JAK/STAT	momelotinib (GS-0387, CYT-387)	in clinical trials		Sierra Oncology	JAK1/2 TKI

SITC IL-6 Supplemental Table 1

STAT3	danvatirsen (AZD9150)	in clinical trials		AstraZeneca	Antisense RNA
IL-1 Modulation					
IL-1	anakinra	FDA-approved	Kineret	Biovitrum (Sweden)	Recombinant IL-1R antagonist
IL-1	rilonacept	FDA-approved	Arcalyst	Regeneron	Receptor trap
IL-1	canakinumab	FDA-approved	Ilaris	Novartis	Human anti-IL-1 β mAb
IL-1	gevokizumab	in clinical trials		Novartis (from Xoma Corporation)	Humanized anti-IL-1 β mAb. Allosteric modulating
IL-1	LY2189102	in clinical trials		Eli-Lilly	Humanized anti-IL-1 β mAb
IL-1	berkemimab (MABp1)	in clinical trials	Xilonix	Xbiotech	Human anti-IL-1 α
IL-1	CYT013	in clinical trials (halted?)		(Kuros) Cytos Biotech and partnerships	therapeutic vaccine (diabetes)
IL-1	MEDI8968	in clinical trials (halted?)		MedImmune (AZ)	Receptor antagonist. Human anti-IL-1RI mAb
IL-1	Isunakinra (EBI-005)	in clinical trials		Buzzard Pharmaceuticals from Eleven Biotherapeutics (now Sesen Bio)	IL-1R inhibitor
IL-1	belnacasan (VX-765)	in clinical trials (halted), preclinical		Vertex	oral caspase I inhibitor
TNFα Modulation					
TNF alpha	infliximab	FDA-approved	Remicade	Janssen	Chimeric anti-TNF α mAb
TNF alpha	etancercept	FDA-approved	Enbrel	Amgen	Receptor trap
TNF alpha	adalimumab	FDA-approved	Humira	AbbVie	Human anti-TNF α mAb
TNF alpha	certulizumab pegol	FDA-approved	Cimzia	UCB	Pegylated humanized anti-TNF α mAb
TNF alpha	golimumab	FDA-approved	Simponi	Janssen	Human anti-TNF α mAb
IL-17/IL-23 Modulation					
IL-17	secukinumab	FDA-approved	Cosentyx	Novartis	Human anti-IL-17 mAb
IL-23	ustekinumab	FDA-approved	Stelara	Janssen	Human anti-IL-12/IL-23 mAb
IL-23	guselkumab	FDA-approved	Tremfya	Janssen	Human anti-IL-23 mAb
IL-23	tildrakizumab -asmn	FDA-approved	Ilumya	Sun Pharma Global	Human anti-IL-23 mAb
IL-23	risankizumab-rzaa	FDA-approved	Skyrizi	AbbVie	Humanized anti-IL-23 mAb

SITC IL-6 Supplemental Table 1

IL-17	ixekizumab	FDA-approved	Taltz	Eli-Lilly	Humanized anti-IL-17A mAb
IL-17	brodalumab	FDA-approved	Siliq	Valeant /LEO Pharma in Europe	Human anti-IL-17A mAb

DRAFT